Jerrelle Copeland, MD
Internal Medicine · Gold Canyon, AZNPI 1790784643
Payments from drug & device makers
Across 219 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$811
- GSK$478
- AbbVie$420
- Amgen$312
- Intra-sana Laboratories$231
- Boehringer Ingelheim$211
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,32699%
- Education$411%
- Entertainment$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 34 | $811 |
| GSK | 25 | $478 |
| AbbVie | 21 | $420 |
| Amgen | 20 | $312 |
| Intra-sana Laboratories | 7 | $231 |
| Boehringer Ingelheim | 12 | $211 |
| AstraZeneca | 14 | $211 |
| Abbott | 8 | $194 |
| Inspire Medical Systems, Inc. | 3 | $150 |
| Lilly USA, LLC | 9 | $140 |
| Johnson & Johnson | 4 | $125 |
| Novartis | 6 | $109 |
| Astellas Pharma US Inc | 4 | $99 |
| Pfizer | 5 | $96 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $84 |
| Sumitomo Pharma America, Inc. | 3 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $68 |
| Exact Sciences | 3 | $60 |
| Phathom Pharmaceuticals, Inc. | 2 | $58 |
| Bardy Diagnostics, Inc. | 4 | $58 |
| Eisai Inc. | 3 | $50 |
| Scilex Pharmaceuticals Inc. | 1 | $48 |
| Bayer | 3 | $46 |
| Ultragenyx Pharmaceutical Inc. | 2 | $45 |
| Kyowa Kirin, Inc. | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Globus Medical | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Saluda Medical Americas, Inc. | 1 | $18 |
| Optos, Inc. | 1 | $17 |
| Emergent Biosolutions Inc. | 1 | $17 |
| Medtronic | 1 | $16 |
| Lucid Diagnostics Inc. | 1 | $14 |
| Vivus LLC | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Reltone 200 Mg$138
- GLYCATE$138
- Reltone 400 Mg$138
- Inspire$113
- Ozempic$102
How this compares
$4,384 in reported general payments places this provider in the 90th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 82 | $101,918 |
| OzempicSemaglutide | 71 | $82,854 |
| EliquisApixaban | 60 | $59,141 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $41,873 |
| WegovySemaglutide | 19 | $26,739 |
| GemtesaVibegron | 32 | $24,453 |
| XareltoRivaroxaban | 22 | $23,573 |
| TrulicityDulaglutide | 11 | $11,708 |
| JardianceEmpagliflozin | 12 | $10,429 |
| Levothyroxine Sodium | 448 | $4,802 |
| Rosuvastatin Calcium | 261 | $4,592 |
| Morphine Sulfate ErMorphine Sulfate | 26 | $4,545 |
| Gabapentin | 191 | $4,407 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 131 | $4,109 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $3,890 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $140 | $113,62693 claims |
| Novo NordiskOzempic, Wegovy | $811 | $109,59390 claims |
| PfizerEliquis, Paxlovid | $96 | $60,57074 claims |
| GSKTrelegy Ellipta | $478 | $41,87340 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $75 | $24,45332 claims |
| Johnson & JohnsonXarelto | $125 | $23,57322 claims |
| Boehringer IngelheimJardiance | $211 | $10,42912 claims |
| AbbVieSynthroid | $420 | $2,98658 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Gold Canyon
- Yessica SachdevaMesa$13.7M
- Louise TaberPhoenix$8.5M
- Janelle WeyerChandler$5.5M
- Robert MutterperlTucson$5.3M
- Jalal AbbasSun City West$4.8M
- Nebojsa SkrepnikTucson$4.7M
- Philip MathewTempe$4.1M
- Justin MoserScottsdale$3.9M
- Franz RischardTucson$3.7M
- Randall SeveranceChandler$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.